Extended Data Fig. 11: Longitudinal evaluation of cytokine profile in post-treatment sera.

a, Longitudinal levels of type 2 cytokines in patients from the Validation Cohort. Three patients (with Patient ID) in the BCA-O group are individually labelled with colour lines. b, c, Longitudinal levels of type 1 cytokines and representative chemokines in patients from the Discovery Cohort (b) and the Validation Cohort (c). Seven patients (with Patient ID) in the BCA-L or BCA-O group are individually labelled with colour lines. d, Comparison of the average type 1 cytokine levels between persistent groups in the Discovery Cohort. The value is the averaged expression of IFN-γ, IL-2, and TNF-α. e, Comparison of the average type 2 cytokine levels at multiple time points between persistent groups in the Validation Cohort. The value represents the average of the normalized expression levels of IL-4, IL-5, and IL-13. f, Comparison of the average type 1 cytokine levels between persistent groups in the Validation Cohort. The value represents the average of the normalized expression levels of IFN-γ, IL-2, and TNF-α. Scatter plot shows mean ± s.e.m. from n = 45 (Baseline), n = 54 (Day 1–5), n =38 (Day 6–8), n = 35 (Day 9–11), n = 36 (Day 12–15), n = 32 (Day 16–19), n = 32 (Day 20–23), n = 54 (Day 25–35), n = 18 (Day 36–63) (d,) and n = 8 (e, f) measurements. Significance levels were calculated with two-tailed Mann-Whitney test (d–f).